Nautilus Biotechnology, Inc.: capital expenditure payments
Capital expenditure payments for Nautilus Biotechnology, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Nautilus Biotechnology, Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 1,277,000 | USD | 2026-02-26 | 10-K · 0001808805-26-000011 |
| 2024-01-01 | 2024-12-31 | 2,122,000 | USD | 2026-02-26 | 10-K · 0001808805-26-000011 |
| 2023-01-01 | 2023-12-31 | 2,442,000 | USD | 2025-02-27 | 10-K · 0001808805-25-000008 |
| 2022-01-01 | 2022-12-31 | 2,324,000 | USD | 2024-02-28 | 10-K · 0001808805-24-000005 |
| 2021-01-01 | 2021-12-31 | 2,269,000 | USD | 2023-02-23 | 10-K · 0001808805-23-000011 |
| 2020-01-01 | 2020-12-31 | 921,000 | USD | 2022-02-24 | 10-K · 0001808805-22-000010 |
Related financial histories
- Nautilus Biotechnology, Inc.: total assets
- Nautilus Biotechnology, Inc.: total liabilities
- Nautilus Biotechnology, Inc.: stockholders equity
- Nautilus Biotechnology, Inc.: cash and cash equivalents
- Nautilus Biotechnology, Inc.: net income or loss
- Nautilus Biotechnology, Inc.: operating cash flow
- Nautilus Biotechnology, Inc.: financing cash flow
- Nautilus Biotechnology, Inc.: investing cash flow
- Nautilus Biotechnology, Inc.: retained earnings or deficit
- Nautilus Biotechnology, Inc.: basic weighted-average shares
- Nautilus Biotechnology, Inc.: diluted weighted-average shares
- Nautilus Biotechnology, Inc.: basic earnings per share
- Nautilus Biotechnology, Inc.: diluted earnings per share
- Nautilus Biotechnology, Inc.: net property, plant and equipment
- Nautilus Biotechnology, Inc.: share-based compensation expense
- Nautilus Biotechnology, Inc.: current assets
- Nautilus Biotechnology, Inc.: current liabilities
- Nautilus Biotechnology, Inc.: current accounts payable
- Nautilus Biotechnology, Inc.: operating expenses
- Nautilus Biotechnology, Inc.: research and development expense
Inspect the source
- Entity
- Nautilus Biotechnology, Inc. / CIK 0001808805
- Captured
- 2026-09-21T17:28:19.888Z
- SEC response SHA-256
d4acdb44768c0b06927cb1c7d522b93d76145f03eca21a78e52bbd595d1e7ed3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001808805.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))